Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,199.37
+0.25 (+0.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
239,718
Open
1,199.12
Bid (Size)
1,180.00 (1)
Ask (Size)
1,199.37 (1)
Prev. Close
1,199.12
Today's Range
1,195.67 - 1,206.81
52wk Range
769.19 - 1,203.49
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Today 7:00 EDT
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
Today 1:00 EDT
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+32.53%
+32.53%
1 Month
+11.19%
+11.19%
3 Month
+23.24%
+23.24%
6 Month
+21.24%
+21.24%
1 Year
+44.35%
+44.35%
More News
Read More
10 Bagger Stocks: Can You Find One?
August 23, 2024
Via
Talk Markets
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
August 23, 2024
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
August 20, 2024
Via
Benzinga
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
August 13, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
August 08, 2024
Via
Benzinga
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
August 20, 2024
Via
Benzinga
Exposures
Product Safety
Regeneron Provides Update on Biologics License Application for Linvoseltamab
August 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Alphabet Turns Twenty
August 19, 2024
Via
Talk Markets
Analyst Ratings For Regeneron Pharmaceuticals
August 02, 2024
Via
Benzinga
7 Stocks That Usually Benefit From a Recession
August 13, 2024
Via
InvestorPlace
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
August 13, 2024
Via
InvestorPlace
3 Biotech Stocks With Promising Drug Pipelines: August 2024
August 08, 2024
Via
InvestorPlace
Exposures
Product Safety
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
August 07, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Healthcare Stocks Positioned for Possible Market Outperformance
August 07, 2024
Via
InvestorPlace
Is Regeneron Pharmaceuticals Due for a Stock Split?
August 03, 2024
Via
The Motley Fool
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
August 01, 2024
Via
Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
August 01, 2024
Via
Investor's Business Daily
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
August 01, 2024
Via
Benzinga
Regeneron Reports Second Quarter 2024 Financial and Operating Results
August 01, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
August 01, 2024
Via
Benzinga
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
July 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.